2025年 新着論文 36 細胞情報学分野から論文が発表されました

In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID

Commun Biol. 2025 Aug 30;8(1):1323. doi: 10.1038/s42003-025-08761-x.

Authors

Affiliations

  • 1 Division of Cell-Free Sciences, Proteo-Science Center, PIAS, Ehime University, Matsuyama, Ehime, Japan.
  • 2 Division of Proteo-Interactome, Proteo-Science Center, PIAS, Ehime University, Matsuyama, Ehime, Japan.
  • 3 Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
  • 4 Division of Cell Signaling, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan. kosako@tokushima-u.ac.jp.
  • 5 Division of Cell-Free Sciences, Proteo-Science Center, PIAS, Ehime University, Matsuyama, Ehime, Japan. sawasaki@ehime-u.ac.jp.

Abstract

Heterobifunctional molecules, such as proteolysis-targeting and autophagy-targeting chimera, represent new drug concepts. They are composed of two protein binders that can induce proximity interactions between two proteins and protein catalysis. Currently, cereblon (CRBN)- and von Hippel-Lindau (VHL)-binders with thalidomide- and VH032-backbones are widely used as E3 ligase binders. Here, we developed a method to validate proteins that interact with heterobifunctional molecules in cells using AirID, a proximity biotinylation enzyme. Interactome of target proteins was validated for six heterobifunctional molecules. ThBD-AirID, a fusion of the thalidomide-binding domain (ThBD) of CRBN and AirID, effectively biotinylated the target proteins. AirID fused to full-length VHL also exhibited highly effective biotinylation. Heterobifunctional molecules with the same target binder but different E3 binders showed different proximity interactome profiles in cells. Analysis using ThBD-AirID revealed a nuclear interaction between androgen receptor and ARV-110. AirID-fused ThBD and VHL could be useful for validating the heterobifunctional molecular interactome in cells.

Conflict of interest statement

Competing interests: The authors declare no competing interests.